Promedior

About Promedior

Promedior is a clinical-stage biotechnology company specializing in the development of targeted therapeutics to treat diseases involving fibrosis, a condition where tissue becomes thickened and scarred. The company's lead product candidate, PRM 151, has demonstrated broad anti-fibrotic activity in multiple preclinical models of fibrotic disease, including pulmonary fibrosis, myelofibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration. Promedior's primary focus is on rare fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF). The company operates in the biotechnology and pharmaceutical markets, serving patients with these rare conditions and collaborating with major pharmaceutical companies like Roche to bring its therapies to market. Promedior's business model involves advancing its therapeutic candidates through clinical trials and partnering with larger pharmaceutical companies to leverage their clinical and commercial expertise. Revenue is generated through these partnerships and potential future sales of approved therapies.